2Department of Cardiology, Erciyes University, School of Medicine, Kayseri, Turkey
3Clinic of Cardiology, Dünya Hospital, Kayseri-Turkey
4Department of Cardiology, Erciyes University, School of Medicine, Kayseri, Turkey
5Department of Cardiology, Erciyes University, School of Medicine, Kayseri, Turkey
6Department of Cardiology, Erciyes University, School of Medicine, Kayseri, Turkey
7Department of Cardiology, Medical Faculty, Erciyes University, Kayseri
8Department of Cardiology, Erciyes University, School of Medicine, Kayseri, Turkey
Abstract
Objective: Our aim was to investigate the effects of serotonin, which is a severe vasoconstrictor agent, on the occurrence of no-reflow phenomenon. Materials and Methods: In this cross-sectional controlled study, 40 patients, admitted to our clinic with chest pain in the first 12 hours and underwent primary percutaneous coronary intervention because of acute myocardial infarction were enrolled. Patients with TIMI 0 grade basal flow and normal post-procedure flow were included in group 1 and patients with flow grade TIMI ≤were enrolled in group 2. To measure the serotonin levels, blood samples were collected from the coronary ostium before the procedure. Results: In group 1, there were 25 patients (20 males, 5 females) and the mean age was 58±11 years; in group 2 there were 15 patients (13 males, 2 females) and the mean age was 62±8 years. The mean serotonin level in platelet in group 1 was 476±208 ng/109 platelet and in group 2-542±273 ng/109 platelet. The difference was not statistically significant (p=0.39). When we compared the serum serotonin levels, it was 41.4±40.8 ng/ml for group 1, but 66.7±45.7 ng/ml for group 2. Although the serum serotonin levels were higher in group 2, the difference was not statistically significant (p=0.07). Conclusion: There was no effect of serotonin level in the development of no-reflow, in patients to whom primary coronary percutaneous intervention was applied.